Skip To Main Content

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

EASD and ADA recommend the addition of basal insulin for people with T2DM who do not achieve glycemic goals on a GLP-1 RA-based regimen.*2,3

RESTORE-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1.

~40% of people with T2DM on GLP-1 RA required intensification with basal insulin after a median of ~2 years (primary endpoint).‡1 Following intensification with basal insulin, a significant reduction in HbA1c was seen§ and no severe hypoglycemia was recorded.¥1

Toujeo® was associated with greater HbA1c and FBG reductions, and similar weight change vs degludec, in people with T2DM switching from GLP-1 RA therapy to basal insulin.

HbA1c-reduction-with-Toujeo

Greater HbA1c reduction with Toujeo® vs degludec was also seen in the propensity score matched sensitivity analysis (p=0.02)†‡1

Baseline characteristics

study-design

Primary endpoint:

proportion of GLP-1 RA ± OAD treated patients who switched to BI or FRC, or added on BI among all GLP-1 RA-treated patients changing their therapy.

Secondary endpoints:

  • Use of other antidiabetic drugs
  • Effectiveness and safety of the different intensification strategies with BI

cohorts

2nd generation basal insulins were associated with greater HbA1c and FBG reductions, and similar weight change vs 1st generation analogs, in people with T2DM adding basal insulin to GLP-1 RA therapy.

Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by adding basal insulin (second- or a first-generation analog) to ongoing GLP-1 RA.1,2

2nd-generation-basal-insulins

2nd-vs-1st-generation-BIs

Despite significant advances in diabetes management, over 50% of people with diabetes remain uncontrolled.*3,4

icon

Prevent long-term complications of T2DM

  1. Each 1% reduction in HbA1c is associated with a significant decrease of long-term complications of T2DM5
icon

Review & intensify treatment

  1. People with T2DM should have their response to treatment reviewed at a regular intervals4,5
  2. People with T2DM who do not achieve adequate control on GLP-1-RA should have their treatment intensified with the addition of basal insulin†6,7
icon

In real-world practice, adding Toujeo® to GLP-1-RA8

  1. Significantly improved glycemic control
  2. Without increasing hypoglycemia
  3. Did not significantly change weight

MAT-BE-2500187 v.1.0 02/2025